Ning Shupeng, Chang Hao-Chen, Fan Kang-Chieh, Hsiao Po-Yu, Feng Chenghao, Shoemaker Devan, Chen Ray T
Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Texas 78758, USA.
Omega Optics, Inc., 8500 Shoal Creek Blvd., Austin, Texas 78757, USA.
Appl Phys Rev. 2023 Jun;10(2):021410. doi: 10.1063/5.0146079.
In the context of continued spread of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 and the emergence of new variants, the demand for rapid, accurate, and frequent detection is increasing. Moreover, the new predominant strain, Omicron variant, manifests more similar clinical features to those of other common respiratory infections. The concurrent detection of multiple potential pathogens helps distinguish SARS-CoV-2 infection from other diseases with overlapping symptoms, which is significant for providing tailored treatment to patients and containing the outbreak. Here, we report a lab-on-a-chip biosensing platform for SARS-CoV-2 detection based on the subwavelength grating micro-ring resonator. The sensing surface is functionalized by specific antibody against SARS-CoV-2 spike protein, which could produce redshifts of resonant peaks by antigen-antibody combination, thus achieving quantitative detection. Additionally, the sensor chip is integrated with a microfluidic chip featuring an anti-backflow Y-shaped structure that enables the concurrent detection of two analytes. In this study, we realized the detection and differentiation of COVID-19 and influenza A H1N1. Experimental results indicate that the limit of detection of our device reaches 100 fg/ml (1.31 fM) within 15 min detecting time, and cross-reactivity tests manifest the specificity of the optical diagnostic assay. Furthermore, the integrated packaging and streamlined workflow facilitate its use for clinical applications. Thus, the biosensing platform presents a promising approach for attaining highly sensitive, selective, multiplexed, and quantitative point-of-care diagnosis and distinction between COVID-19 and influenza.
在严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)持续传播以及新变种出现的背景下,对快速、准确且频繁检测的需求不断增加。此外,新的优势毒株奥密克戎变种表现出与其他常见呼吸道感染更为相似的临床特征。同时检测多种潜在病原体有助于将SARS-CoV-2感染与其他有重叠症状的疾病区分开来,这对于为患者提供针对性治疗以及控制疫情爆发具有重要意义。在此,我们报告一种基于亚波长光栅微环谐振器的用于SARS-CoV-2检测的芯片实验室生物传感平台。传感表面通过针对SARS-CoV-2刺突蛋白的特异性抗体进行功能化,该抗体可通过抗原 - 抗体结合产生谐振峰的红移,从而实现定量检测。此外,传感器芯片与具有防回流Y形结构的微流控芯片集成,能够同时检测两种分析物。在本研究中,我们实现了对COVID-19和甲型H1N1流感的检测与区分。实验结果表明,我们的设备在15分钟检测时间内检测限达到100 fg/ml(1.31 fM),交叉反应测试表明了光学诊断测定的特异性。此外,集成包装和简化的工作流程便于其用于临床应用。因此,该生物传感平台为实现高灵敏度、选择性、多重和定量的即时护理诊断以及区分COVID-19和流感提供了一种有前景的方法。